Search
Showing results for "1"
A list of the Children's Diabetes Centre's research track record.
Citation: Libman I, Haynes A, Lyons S, Pradeep P, Rwagasor E, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Definition, epidemiology, and
Rare diseases (RD) are conditions affecting fewer than 1 in 2000 persons, with over 7000 largely genetic RDs affecting 3.5 %-5.9 % of the global population, or approximately 262.9–446.2 million people. The substantial healthcare burden and costs, such as the $1 trillion annual expense in the USA, highlight the urgent need for improved RD management. The International Rare Diseases Research Consortium (IRDiRC) addresses this need through global collaboration, aiming for timely and accurate diagnosis, development of 1000 new therapies, and methodologies to measure impact by 2027.
Citation: Sek K, Chen AXY, Cole T, Armitage JD, Tong J, ……… Waithman J, Parish IA, et al. Tumor site-directed A1R expression enhances CAR T cell
Citation: MacDonald B, Burmaz M, Baker S, et al. TrialR: critical enablers and the need for reusable Rare Disease Clinical Trial infrastructure in
Many of the Centre's researchers have been responsible for discovering and contributing to real game-changers, making a difference to children with diabetes.
Summer holidays here we come! The holidays are finally here and while a lack of routine is welcomed by most, being out of routine can be challenging
We are excited to announce that applications are now open for our PhD scholarships and our Honours/Masters scholarships to support students pursuing
ENDIA (Environmental Determinants of Islet Autoimmunity) is a national observational study into the causes of Type 1 Diabetes in childhood.
ACE inhibitors and statins are well tolerated in teenagers with Type 1 Diabetes but more evidence is required to demonstrate whether they are effective